Real -world incidence of endophthalmitis after intravitreal anti-VEGF injections: findings from the Common Data Model in ophthalmology
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
OBJECTIVES: The aim of this study was to evaluate the real-world incidence of endophthalmitis after intravitreal anti-vascular endothelial growth factor (VEGF) injections using data from the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). METHODS: Patients with endophthalmitis that developed within 6 weeks after intravitreal anti-VEGF injections were identified in 3 large OMOP CDM databases. RESULTS: We identified 23,490 patients who received 128,123 intravitreal anti-VEGF injections. The incidence rates of endophthalmitis were 15.75 per 10,000 patients and 2.97 per 10,000 injections. The incidence rates of endophthalmitis for bevacizumab, ranibizumab, and aflibercept (per 10,000 injections) were 3.65, 1.39, and 0.76, respectively. The annual incidence has remained below 5.00 per 10,000 injections since 2011 despite the increasing number of intravitreal anti-VEGF injections. Bevacizumab presented a higher incidence rate for endophthalmitis than ranibizumab and aflibercept (incidence rate ratio, 3.17; p= 0.021). CONCLUSIONS: The incidence of endophthalmitis after intravitreal anti-VEGF injections has stabilized since 2011 despite the explosive increase in anti-VEGF injections. The off-label use of bevacizumab accounted for its disproportionately high incidence of endophthalmitis. The OMOP CDM, which includes off-label uses, laboratory data, and a scalable standardized database, could provide a novel strategy to reveal real-world evidence, especially in ophthalmology.
Abstract
OBJECTIVES: The aim of this study was to evaluate the real-world incidence of endophthalmitis after intravitreal anti-vascular endothelial growth factor (VEGF) injections using data from the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). METHODS: Patients with endophthalmitis that developed within 6 weeks after intravitreal anti-VEGF injections were identified in 3 large OMOP CDM databases. RESULTS: We identified 23,490 patients who received 128,123 intravitreal anti-VEGF injections. The incidence rates of endophthalmitis were 15.75 per 10,000 patients and 2.97 per 10,000 injections. The incidence rates of endophthalmitis for bevacizumab, ranibizumab, and aflibercept (per 10,000 injections) were 3.65, 1.39, and 0.76, respectively. The annual incidence has remained below 5.00 per 10,000 injections since 2011 despite the increasing number of intravitreal anti-VEGF injections. Bevacizumab presented a higher incidence rate for endophthalmitis than ranibizumab and aflibercept (incidence rate ratio, 3.17; p= 0.021). CONCLUSIONS: The incidence of endophthalmitis after intravitreal anti-VEGF injections has stabilized since 2011 despite the explosive increase in anti-VEGF injections. The off-label use of bevacizumab accounted for its disproportionately high incidence of endophthalmitis. The OMOP CDM, which includes off-label uses, laboratory data, and a scalable standardized database, could provide a novel strategy to reveal real-world evidence, especially in ophthalmology.
참고문헌 (31)
- Flaxman SR, "Global causes of blindness and distance vision impairment 1990-2020 : a systematic review and meta-analysis", Lancet Glob Health, 5, pp.e1221~e1234 (2017)
- Falavarjani KG, "Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy", Eye(Lond), 24, pp.717~719 (2010)
- Nazari H, "Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity(ROP)associated with vitreous or retinal hemorrhage", Graefes Arch Clin Exp Ophthalmol, 248, pp.1713~1718 (2010)
- Schmidt-Erfurth U, "Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists(EURETINA)", Br J Ophthalmol, 98, pp.1144~1167 (2014)
- Schmidt-Erfurth U, "Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists(EURETINA)", Ophthalmologica, 237, pp.185~222 (2017)
- Schmidt-Erfurth U, "Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists(EURETINA)", Ophthalmologica, 242, pp.123~162 (2019)
- Lyall DA, "Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes", Eye(Lond), 26, pp.1517~1526 (2012)
- Falavarjani KG, "Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature", Eye(Lond), 27, pp.787~794 (2013)
- Kiss S, "Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections : a USA claims analysis", Clin Ophthalmol, 12, pp.1625~1635 (2018)
- Baudin F, "Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti-vascular growth factor agents in a nationwide study in France", JAMA Ophthalmol, 136, pp.1352~1358 (2018)
- Stang PE, "Advancing the science for active surveillance : rationale and design for the Observational Medical Outcomes Partnership", Ann Intern Med, 153, pp.600~606 (2010)
- "The book of OHDSI"[URL]
- Reich C, "Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases", J Biomed Inform, 45, pp.689~696 (2012)
- "SNOMED CT"[URL]
- "LOINC"[URL]
- "RxNorm"[URL]
- "OHDSI THEMIS"[URL]
- Avery RL, "Intravitreal injection technique and monitoring : updated guidelines of an expert panel", Retina, 34(Suppl 12), pp.S1~S18 (2014)
- Roth DB, "Antibiotic selection in the treatment of endophthalmitis : the significance of drug combinations and synergy", Surv Ophthalmol, 41, pp.395~401 (1997)
- Xu K, "Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors : management and visual outcomes", Ophthalmology, 125, pp.1279~1286 (2018)
- Dossarps D, "FRCR net (FRenCh Retina specialists net)", Am J Ophthalmol, 160, pp.17~25 (2015)
- VanderBeek BL, "Association of compounded bevacizumab with postinjection endophthalmitis", JAMA Ophthalmol, 133, pp.1159~1164 (2015)
- Lee SH, "Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab", Eye(Lond), 24, pp.226~232 (2010)
- Storey PP, "Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents", Can J Ophthalmol, 55, pp.286~292 (2020)
- Sherman RE, "Real-world evidence - what is it and what can it tell us?", N Engl J Med, 375, pp.2293~2297 (2016)
- Corrigan-Curay J, "Real-world evidence and real-world data for evaluating drug safety and effectiveness", JAMA, 320, pp.867~868 (2018)
- Hripcsak G, "Observational Health Data Sciences and Informatics(OHDSI) : opportunities for observational researchers", Stud Health Technol Inform, 216, pp.574~578 (2015)
- Suchard MA, "Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes : a systematic, multinational, large-scale analysis", Lancet, 394, pp.1816~1826 (2019)
- Vashisht R, "Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin : analysis from the observational health data sciences and informatics Initiative", JAMA Netw Open, 1, pp.e181755~ (2018)
- Choi SA, "Analysis of antiseizure drug-related adverse reactions from the electronic health record using the common data model", Epilepsia, 61, pp.610~616 (2020)
- Konrad R, "Key considerations when using health insurance claims data in advanced data analyses: an experience report", Health Syst(Basingstoke), 9, pp.317~325 (2019)